Abstract
Rationale Hemorheological alterations are reported in obstructive sleep apnea (OSA) and reversed with continuous positive airway pressure (CPAP), observations potentially explained by intermittent hypoxia (IH)-induced oxidative stress.
Objective To investigate whether IH causes hemorheological alterations viaoxidative stress.
Methods Wistar rats were exposed to normoxia (n=7) or IH (n=8) for 14 days. Twenty-three moderate-to-severe OSA patients were assessed at three time points: baseline, after randomisation to either 2 weeks of nocturnal oxygen (n=13) or no treatment (n=10), and after 1-month of CPAP treatment (n=17). Further, an OSA-free control group (n=13) was assessed at baseline and after time-matched follow-up.
Measurements We measured hemorheological parameters [hematocrit, blood viscosity, plasma viscosity (rats only), erythrocyte aggregation and deformability (humans only)] and redox balance (SOD, GPX, protein oxidation [AOPP] and lipid peroxidation [MDA]). We also tested erythrocytes hemorheological sensitivity to reactive oxygen species (ROS) in our human participants using the oxidant t-butyl hydroperoxide (TBHP).
Results In rats, IH increased blood viscosity by increasing hematocrit without altering erythrocytes hemorheological properties. IH also reduced SOD activity and increased AOPP. In humans, baseline hemorheological properties were similar between patients and controls, and properties were unaltered following oxygen and CPAP, except erythrocyte deformability was reduced following oxygen therapy. Redox balance was comparable between patients and controls. At baseline, TBHP induced a greater reduction of erythrocyte deformability in patients while CPAP reduced TBHP-induced increase in aggregation strength.
Conclusion IH and OSA per se do not cause hemorheological alterations despite the presence of oxidative stress or higher sensitivity to ROS, respectively.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Waltz has nothing to disclose.
Conflict of interest: Dr. Beaudin reports other from Canadian Institutes of Health Research - Heart and Stroke Foundation of Canada (HSFC), other from Alberta Innovates-Health Solutions (AIHS), from University of Calgary, during the conduct of the study.
Conflict of interest: Dr. Beladi has nothing to disclose.
Conflict of interest: Dr. Raneri has nothing to disclose.
Conflict of interest: Dr. Pépin reports grants and other from Air Liquide Foundation, grants, personal fees and other from Agiradom, grants, personal fees and other from AstraZeneca, grants and personal fees from Fisher and Paykel, grants and personal fees from Mutualia, grants, personal fees and other from Philips, grants, personal fees and other from Resmed, grants and personal fees from Vitalaire, personal fees from Boehringer Ingelheim, personal fees from Jazz Pharmaceutical, personal fees from Night Balance, personal fees from Sefam, outside the submitted work.
Conflict of interest: Dr. Pialoux has nothing to disclose.
Conflict of interest: Dr. Hanly has nothing to disclose.
Conflict of interest: Dr. Verges has nothing to disclose.
Conflict of interest: Dr. Poulin has nothing to disclose.
- Received February 4, 2021.
- Accepted April 8, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org